Loading...
  • Hepatology
  • Gastroenterology and Hepatology is the first journal to cover the latest advances in pathology of the gastrointestinal tract, liver, pancreas, and bile ducts, making it an indispensable tool for gastroenterologists, hepatologists, internists and general practitioners. (elsevier.es)
  • Acetaminophen poisoning has become the most common cause of acute liver failure in the United States," report the authors of a new study in the December 2005 issue of Hepatology, the official journal of the American Association for the Study of Liver Diseases (AASLD). (medicalnewstoday.com)
  • R. Todd Frederick, Dr. Frederick is Director of Quality and Clinical Protocols for the Hepatology and Liver Transplant Program at California Pacific Medical Center in San Francisco, California. (pubmedcentralcanada.ca)
  • RAB received a grant from the Canadian Association for the Study of the Liver (CASL) to accomplish her hepatology fellowship. (springer.com)
  • jaundice
  • Presenting with jaundice and epigastric pain, a woman with a history of multiple malignancies was admitted directly for an ultrasound-guided liver biopsy. (ahrq.gov)
  • ACLF
  • There were 53 ACLF patients and 53 patients without ACLF in this study. (hindawi.com)
  • Elevated CRP is an accurate marker for diagnosing bacterial infection in autoimmune liver disease-associated ACLF patients. (hindawi.com)
  • Several patients with ACLF have been recently reported [ 3 - 7 ]. (hindawi.com)
  • Some studies considered hepatic encephalopathy, low-serum sodium, and high INR as predictors of poor outcome in ACLF patients [ 3 , 5 ]. (hindawi.com)
  • However, few studies about autoimmune liver disease-induced ACLF patients are available to date. (hindawi.com)
  • We retrospectively analyzed the data of all patients admitted at the infectious disease wards of the First Affiliated Hospital, College of Medicine, Zhejiang University, China, and diagnosed with autoimmune liver disease-associated ACLF from August 2012 to August 2017. (hindawi.com)
  • In this study, we try to assess the association between expression of NK cells and its receptors and prognosis of patients with ACLF in advanced phase. (scirp.org)
  • According to whether their total bilirubin within 7 days of average daily rise is ≥17.1 umol/L or not, we differentiated patients with ACLF into advanced phase and not-advanced phase. (scirp.org)
  • All patients' total bilirubin within 7 days of average daily rise is ≥17.1 umol/L. Patients were excluded if they had some special conditions such as concomitant autoimmune diseases, important organ dysfunctions not due to ACLF malignancies, pregnancy and lactation, excessive alcohol drinking within 6 months. (scirp.org)
  • diagnosis
  • The need to recognize and treat the diverse and often subtle presentations of HE is also becoming increasingly evident, as proper diagnosis and management are critical in order to improve quality of life, prevent recurrences and hospitalizations, and potentially prolong lives. (pubmedcentralcanada.ca)
  • Early and correct diagnosis is essential for further management of patients, since diagnosis impacts therapy choice. (springer.com)
  • overt
  • While HE is generally considered to be a reversible condition, some new data suggest that patients may not return to previous levels of cognitive functioning after episodes of overt HE. (pubmedcentralcanada.ca)
  • Portosystemic
  • Portal systemic shunting may be due to various causes of portal hypertension (e.g., portal vein thrombosis), but can also be iatrogenic as in patients that have undergone a transjugular intrahepatic portosystemic shunt (TIPS) procedure. (clinicaladvisor.com)
  • urea
  • Glycerol phenylbutyrate, an investigational drug, is a pre-pro-drug of phenylacetic acid, the active moiety of BUPHENYL®, the only branded therapy currently FDA-approved as adjunctive therapy for the chronic management of patients with the most prevalent urea cycle disorders. (cnbc.com)
  • placebo
  • A post-hoc analysis of the same primary endpoint revealed patients with confirmed hyperammonemia at randomization (baseline) improved faster on OCR-002 than placebo (42 versus 63 hours, respectively), with statistical significance, p=0.034. (globenewswire.com)
  • The study enrolled 178 total patients, of whom 59 were on Rifaximin at baseline, including 29 in the placebo arm and 30 in the active arm. (cnbc.com)
  • The HALT-HE study was a Phase II, multi-center, randomized, double-blind trial of glycerol phenylbutyrate vs. placebo in 178 patients with episodic HE recruited from 28 sites in the United States, 9 sites in Russia and 7 sites in Ukraine. (cnbc.com)
  • 88 patients were randomized to the placebo group and 90 to the GPB arm. (cnbc.com)
  • 55 patients in the GPB arm and 67 patients in the placebo arm completed the study. (cnbc.com)
  • 6 placebo-controlled studies involving 641 patients (326 assigned to flumazenil and 315 assigned to placebo) met the selection criteria. (acpjc.org)
  • 1 trial reported adverse events in 4 patients assigned flumazenil (no mention was made of patients in the placebo group), and 1 trial showed no adverse effects in either group. (acpjc.org)
  • outcomes
  • Neuroprotective agents that can limit secondary tissue loss and/or improve behavioral outcomes have been identified in multiple animal models of acute brain injury. (biomedcentral.com)
  • diseases
  • SOUTH SAN FRANCISCO, Calif., Nov. 12, 2012 (GLOBE NEWSWIRE) -- Hyperion Therapeutics, Inc. (Nasdaq:HPTX) announced today that the results of the Phase 2 HALT-HE Study were presented at the Presidential Plenary Session I of the 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) (The Liver Meeting®), in Boston, MA. (cnbc.com)
  • Abdominal
  • After the procedure, the patient had low blood pressure and complained of new abdominal pain, which worsened over the next 2 hours. (ahrq.gov)
  • 2016
  • 2016 was a busy year for Ocera, culminating with the timely completion of enrollment in the fourth quarter of STOP-HE, a landmark study evaluating intravenous OCR-002 (ornithine phenylacetate) in patients hospitalized with acute hepatic encephalopathy (HE)," said Linda Grais, M.D., Chief Executive Officer of Ocera. (cnbc.com)